newsfilter
← Latest News
GlobeNewswire·

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for